Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, medical devices, and cosmetics.
As part of a succession solution, the Ewopharma Group was able to acquire Neomed s.r.o. as of 1 June 2023. In the past, Ewopharma and Neomed enjoyed several specific, successful collaborations in the region.
Over the past years, Ewopharma has successfully grown the business and continued to expand geographically. The acquisition opens new expertise for Ewopharma, this with Neomed's existing staff and partnerships.
Mr. Alain Staub, CEO of the Ewopharma Group, commented “This is an important milestone for the Ewopharma Group, allowing us to establish a logistics hub centrally located in our markets to respond even faster to patient demand, and we are excited with this prospect. The experienced team at Neomed, led by Ivo Filípek and Jan Krejčí, will be instrumental in the company's continued business growth. We are convinced that this acquisition will create a large number of additional jobs.”
Neomed will continue to provide the products of its partners in the fields of pharmaceutical and aesthetic medicine, dermatology, and cosmetic products, as well as microsurgical instruments and intraocular lenses to doctors, clinics, and patients with the usual important level of reliability.
Moreover, the existing warehouse infrastructure will be significantly expanded to accommodate the joint synergies and growth of Neomed and Ewopharma even better.
About Neomed s.r.o
Neomed s.r.o. is a company engaged in the distribution of pharmaceuticals, medical devices, and cosmetics. The company has been in the market since 1998 to provide specialized distribution and marketing services to foreign producers who are not familiar with the Czech and Slovak markets or whose turnover is not profitable for direct participation.
As part of a succession solution, the Ewopharma Group was able to acquire Neomed s.r.o. as of 1 June 2023. In the past, Ewopharma and Neomed enjoyed several specific, successful collaborations in the region.
Over the past years, Ewopharma has successfully grown the business and continued to expand geographically. The acquisition opens new expertise for Ewopharma, this with Neomed's existing staff and partnerships.
Mr. Alain Staub, CEO of the Ewopharma Group, commented “This is an important milestone for the Ewopharma Group, allowing us to establish a logistics hub centrally located in our markets to respond even faster to patient demand, and we are excited with this prospect. The experienced team at Neomed, led by Ivo Filípek and Jan Krejčí, will be instrumental in the company's continued business growth. We are convinced that this acquisition will create a large number of additional jobs.”
Neomed will continue to provide the products of its partners in the fields of pharmaceutical and aesthetic medicine, dermatology, and cosmetic products, as well as microsurgical instruments and intraocular lenses to doctors, clinics, and patients with the usual important level of reliability.
Moreover, the existing warehouse infrastructure will be significantly expanded to accommodate the joint synergies and growth of Neomed and Ewopharma even better.
About Neomed s.r.o
Neomed s.r.o. is a company engaged in the distribution of pharmaceuticals, medical devices, and cosmetics. The company has been in the market since 1998 to provide specialized distribution and marketing services to foreign producers who are not familiar with the Czech and Slovak markets or whose turnover is not profitable for direct participation.
